Open AccessGingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen
Author(s) -
Ekholm Heidi M.,
Löyttyniemi Eliisa,
Soukka Tero,
Rautava Jaana
Publication year - 2021
Publication title -
clinical and experimental dental research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.464
H-Index - 9
ISSN - 2057-4347
DOI - 10.1002/cre2.382
Subject(s) - antiestrogen , denosumab , fibroblast , cell growth , viability assay , keratinocyte , medicine , corticosteroid , endocrinology , cell , pharmacology , chemistry , estrogen receptor , osteoporosis , in vitro , cancer , biochemistry , breast cancer
Objectives Antiresorptive treatment has been shown to impair mucosal cell proliferation, migration, and viability. However, in the clinic, antiresorptives are often used in combination with other drugs. We studied the effect of antiresorptives combined with a corticosteroid or antiestrogen on oral mucosal keratinocytes and fibroblasts. Material and methods Human gingival keratinocyte and fibroblast cell lines were exposed to bisphosphonates (BPs) and denosumab in different concentrations and durations together with an antiestrogen or corticosteroid. Changes in cell viability, proliferation and migration after exposures were measured. Data were evaluated with hierarchical linear mixed model for repeated measurements. Results Bisphosphonate exposure suppressed keratinocyte and fibroblast cell viability, proliferation, and migration in a time‐dependent manner. Combining a corticosteroid or antiestrogen with BPs further increased this negative effect. Denosumab alone had a mild positive effect on keratinocyte and fibroblast growth. When denosumab was combined with a corticosteroid or antiestrogen, cell growth was suppressed. Conclusions Our results show that coexisting medications may increase the negative impact of BPs or denosumab on oral mucosal cells.